Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam F Cohen

Showing results (31-40 of 146) with videos related to

Pageof 15
Sort By:
BMJ (Clinical Research Ed.)|July 24, 2015
Need for a proactive and structured approach to risk analysis when designing phase I trialsCornelis A Van den Bogert, Adam F Cohen
British Journal of Clinical Pharmacology|June 1, 2011
TolvaptanEline A Dubois, Robert Rissmann, Adam F Cohen
BMJ (Clinical Research Ed.)|June 7, 2014
New EU clinical trials regulationAnna E Westra, Wendy Bos, Adam F Cohen
British Journal of Clinical Pharmacology|February 24, 2015
LomitapideSebastiaan C Goulooze, Adam F Cohen, Robert Rissmann
British Journal of Clinical Pharmacology|March 31, 2015
MirabegronSebastiaan C Goulooze, Adam F Cohen, Robert Rissmann
Drug Discovery Today|March 25, 2014
Towards a sustainable system of drug developmentEllen H M Moors, Adam F Cohen, Huub Schellekens
British Journal of Clinical Pharmacology|April 8, 2015
Vemurafenib/dabrafenib and trametinibRobert Rissmann, Marleen H M Hessel, Adam F Cohen
British Journal of Clinical Pharmacology|May 21, 2016
Sofosbuvir and daclatasvirMarleen H M Hessel, Adam F Cohen, Robert Rissmann
Clinical Pharmacology and Therapeutics|December 28, 2021
De-risking Clinical Trials: The BIAL Phase I Trial in ForesightAdam F Cohen, Jeroen van Smeden, David J Webb
The Lancet. Psychiatry|August 29, 2016
Question-based Drug Development for psilocybinFrancis M Dijkstra, Gabriel E Jacobs, Adam F Cohen
Pageof 15

Showing results (31-40 of 146) with videos related to

Sort By:
Pageof 15
BMJ (Clinical Research Ed.)|July 24, 2015
Need for a proactive and structured approach to risk analysis when designing phase I trialsCornelis A Van den Bogert, Adam F Cohen
British Journal of Clinical Pharmacology|June 1, 2011
TolvaptanEline A Dubois, Robert Rissmann, Adam F Cohen
BMJ (Clinical Research Ed.)|June 7, 2014
New EU clinical trials regulationAnna E Westra, Wendy Bos, Adam F Cohen
British Journal of Clinical Pharmacology|February 24, 2015
LomitapideSebastiaan C Goulooze, Adam F Cohen, Robert Rissmann
British Journal of Clinical Pharmacology|March 31, 2015
MirabegronSebastiaan C Goulooze, Adam F Cohen, Robert Rissmann
Drug Discovery Today|March 25, 2014
Towards a sustainable system of drug developmentEllen H M Moors, Adam F Cohen, Huub Schellekens
British Journal of Clinical Pharmacology|April 8, 2015
Vemurafenib/dabrafenib and trametinibRobert Rissmann, Marleen H M Hessel, Adam F Cohen
British Journal of Clinical Pharmacology|May 21, 2016
Sofosbuvir and daclatasvirMarleen H M Hessel, Adam F Cohen, Robert Rissmann
Clinical Pharmacology and Therapeutics|December 28, 2021
De-risking Clinical Trials: The BIAL Phase I Trial in ForesightAdam F Cohen, Jeroen van Smeden, David J Webb
The Lancet. Psychiatry|August 29, 2016
Question-based Drug Development for psilocybinFrancis M Dijkstra, Gabriel E Jacobs, Adam F Cohen
Pageof 15